1
|
Zhang QQ, Wu XJ, Tang T, Zhu SW, Yao Q,
Gao BZ and Yuan XC: Quantitative analysis of rectal cancer by
spectral domain optical coherence tomography. Phys Med Biol.
57:5235–5244. 2012. View Article : Google Scholar : PubMed/NCBI
|
2
|
Ades S: Adjuvant chemotherapy for colon
cancer in the elderly: Moving from evidence to practice. Oncology
(Williston Park). 23:162–167. 2009.PubMed/NCBI
|
3
|
Jensen NF, Stenvang J, Beck MK, Hanáková
B, Belling KC, Do KN, Viuff B, Nygård SB, Gupta R, Rasmussen MH, et
al: Establishment and characterization of models of chemotherapy
resistance in colorectal cancer: Towards a predictive signature of
chemoresistance. Mol Oncol. 9:1169–1185. 2015. View Article : Google Scholar : PubMed/NCBI
|
4
|
McGuire WP, Hoskins WJ, Brady MF, Kucera
PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M:
Cyclophosphamide and cisplatin compared with paclitaxel and
cisplatin in patients with Stage III and Stage IV Ovarian Cancer. N
Engl J Med. 334:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
|
5
|
Holmes FA, Walters RS, Theriault RL,
Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK and Hortobagyi
GN: Phase II Trial of taxol, an active drug in the treatment of
metastatic breast cancer. J Natl Cancer Inst. 83:1797–1805. 1991.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Murphy WK, Fossella FV, Winn RJ, Shin DM,
Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, et
al: Phase II study of taxol in patients with untreated advanced
non-small-cell lung cancer. J Natl Cancer Inst. 85:384–388. 1993.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Rowinsky EK and Donehower RC: Paclitaxel
(taxol). N Engl J Med. 332:1004–1014. 1995. View Article : Google Scholar : PubMed/NCBI
|
8
|
Einzig AI, Neuberg D, Wiernik PH, Grochow
LB, Ramirez G, O'Dwyer PJ and Petrelli NJ: Phase II trial of
paclitaxel in patients with advanced colon cancer previously
untreated with cytotoxic chemotherapy: An eastern cooperative
oncology group trial (PA286). Am J Ther. 3:750–754. 1996.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Orr GA, Verdier-Pinard P, Mcdaid H and
Horwitz SB: Mechanisms of taxol resistance related to microtubules.
Oncogene. 22:7280–7295. 2003. View Article : Google Scholar : PubMed/NCBI
|
10
|
Tsai HC, Huang CY, Su HL and Tang CH: CTGF
increases drug resistance to paclitaxel by upregulating survivin
expression in human osteosarcoma cells. Biochim Biophys Acta.
1843:846–854. 2014. View Article : Google Scholar : PubMed/NCBI
|
11
|
Wu G, Qin XQ, Guo JJ, Li TY and Chen JH:
AKT/ERK activation is associated with gastric cancer cell
resistance to paclitaxel. Int J Clin Exp Pathol. 7:1449–1458.
2014.PubMed/NCBI
|
12
|
Du G, Yang Y, Zhang Y, Sun T, Liu W, Wang
Y, Li J and Zhang H: Thrombocytosis and immunohistochemical
expression of connexin 43 at diagnosis predict survival in advanced
non-small-cell lung cancer treated with cisplatin-based
chemotherapy. Cancer Chemother Pharmacol. 71:893–904. 2013.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Yu BB, Dong SY, Yu ML, Jiang GJ, Ji J and
Tong XH: Total flavonoids of litsea coreana enhance the
cytotoxicity of oxaliplatin by increasing gap junction
intercellular communication. Biol Pharm Bull. 37:1315–1322. 2014.
View Article : Google Scholar : PubMed/NCBI
|
14
|
King TJ and Bertram JS: Connexins as
targets for cancer chemoprevention and chemotherapy. Biochim
Biophys Acta. 1719:146–160. 2005. View Article : Google Scholar : PubMed/NCBI
|
15
|
Yamasaki H and Naus CC: Role of connexin
genes in growth control. Carcinogenesis. 17:1199–1213. 1996.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Park JM, Munoz JL, Wona BW, Bliss SA,
Greco SJ, Patel SA, Kandouz M and Rameshwar P: Exogenous CXCL12
activates protein kinase C to phosphorylate connexin 43 for gap
junctional intercellular communication among confluent breast
cancer cells. Cancer Lett. 331:84–91. 2013. View Article : Google Scholar : PubMed/NCBI
|
17
|
Sirnes S, Bruun J, Kolberg M, Kjenseth A,
Lind GE, Svindland A, Brech A, Nesbakken A, Lothe RA, Leithe E and
Rivedal E: Connexin43 acts as a colorectal cancer tumor suppressor
and predicts disease outcome. Int J Cancer. 131:570–581. 2012.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Wang Y, Zhang S, Zhang C, Zhao Z, Zheng X,
Xue L, Liu J and Yuan XC: Investigation of an SPR biosensor for
determining the influence of connexin 43 expression on the
cytotoxicity of cisplatin. Analyst. 141:3411–3420. 2016. View Article : Google Scholar : PubMed/NCBI
|
19
|
Shimomura M, Yaoi T, Itoh K, Kato D,
Terauchi K, Shimada J and Fushiki S: Drug resistance to paclitaxel
is not only associated with ABCB1 mRNA expression but also with
drug accumulation in intracellular compartments in human lung
cancer cell lines. Int J Oncol. 40:995–1004. 2012.PubMed/NCBI
|
20
|
Hong X, Wang Q, Yang Y, Zheng S, Tong X,
Zhang S, Tao L and Harris AL: Gap junctions propagate opposite
effects in normal and tumor testicular cells in response to
cisplatin. Cancer Lett. 317:165–171. 2012. View Article : Google Scholar : PubMed/NCBI
|
21
|
Porter AG and Jänicke RU: Emerging roles
of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Jordan MA and Kamath K: How do
microtubule-targeted drugs work? An overview. Curr Cancer Drug
Targets. 7:730–742. 2007. View Article : Google Scholar : PubMed/NCBI
|
23
|
Wolf F, Wandke C, Isenberg N and Geley S:
Dose-dependent effects of stable cyclin B1 on progression through
mitosis in human cells. EMBO J. 25:2802–2813. 2006. View Article : Google Scholar : PubMed/NCBI
|
24
|
Ito M: Factors controlling cyclin B
expression. Plant Mol Biol. 43:677–690. 2000. View Article : Google Scholar : PubMed/NCBI
|
25
|
Li F and Altieri DC: The cancer
antiapoptosis mouse survivin gene: Characterization of locus and
transcriptional requirements of basal and cell cycle-dependent
expression. Cancer Res. 59:3143–3151. 1999.PubMed/NCBI
|
26
|
Mesnil M, Piccoli C, Tiraby G, Willecke K
and Yamasaki H: Bystander killing of cancer cells by herpes simplex
virus thymidine kinase gene is mediated by connexins. Proc Natl
Acad Sci USA. 93:pp. 1831–1835. 1996; View Article : Google Scholar : PubMed/NCBI
|
27
|
Munoz JL, Rodriguez-Cruz V, Greco SJ,
Ramkissoon SH, Ligon KL and Rameshwar P: Temozolomide resistance in
glioblastoma cells occurs partly through epidermal growth factor
receptor-mediated induction of connexin 43. Cell Death Dis.
5:e11452014. View Article : Google Scholar : PubMed/NCBI
|
28
|
Tang N, Wang Q, Wu D, Zhang S, Zhang Y and
Tao L: Differential effects of paclitaxel and docetaxel on gap
junctions affects their cytotoxicities in transfected HeLa cells.
Mol Med Rep. 8:638–644. 2013.PubMed/NCBI
|
29
|
Sato H, Iwata H, Takano Y, Yamada R,
Okuzawa H, Nagashima Y, Yamaura K, Ueno K and Yano T: Enhanced
effect of connexin 43 on cisplatin-induced cytotoxicity in
mesothelioma cells. J Pharmacol Sci. 110:466–475. 2009. View Article : Google Scholar : PubMed/NCBI
|
30
|
Hong R and Lim SC: Pathological
significance of connexin 26 expression in colorectal
adenocarcinoma. Oncol Rep. 19:913–919. 2008.PubMed/NCBI
|
31
|
Kanczuga-Koda L, Koda M, Sulkowski S,
Wincewicz A, Zalewski B and Sulkowska M: Gradual loss of functional
gap junction within progression of colorectal cancer-a shift from
membranous CX32 and CX43 expression to cytoplasmic pattern during
colorectal carcinogenesis. In Vivo. 24:101–107. 2010.PubMed/NCBI
|
32
|
Han Y, Zhang PJ, Chen T, Yum SW, Pasha T
and Furth EE: Connexin43 expression increases in the epithelium and
stroma along the colonic neoplastic progression pathway:
Implications for its oncogenic role. Gastroenterol Res Pract.
2011:5617192011. View Article : Google Scholar : PubMed/NCBI
|
33
|
Ezumi K, Yamamoto H, Murata K, Higashiyama
M, Damdinsuren B, Nakamura Y, Kyo N, Okami J, Ngan CY and Takemasa
I: Aberrant expression of connexin 26 is associated with lung
metastasis of colorectal cancer. Clin Cancer Res. 14:677–684. 2008.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Giessmann D, Theiss C, Breipohl W and
Meller K: Decreased gap junctional communication in neurobiotin
microinjected lens epithelial cells after taxol treatment. Anat
Embryol (Berl). 209:391–400. 2005. View Article : Google Scholar : PubMed/NCBI
|